Day Zero Diagnostics Inc.
- UEI
- KZKSJLYEAE83
- CAGE
- 7PXR9
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Website
- biomerieux.com
- Founded
- 1963
- Employees
- 10K-50K
- Estimated annual revenue
- $1B-$10B
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $13,925 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Day zero diagnostics testing services needed by the department of laboratory medicine (DLM) for existing project. | NIH Clinical Center | $13,925 |
Contract subawards
| Prime contractor | Prime award | Amount | Awarded |
|---|---|---|---|
| Trustees Of Boston University | 75A50122C00028 | $1,499,992 | |
| Trustees Of Boston University | 75A50122C00028 | $622,358 |
Grant awards
Similar vendors
About the company
Day Zero Diagnostics Inc. is a for-profit corporate entity based in East Watertown, Massachusetts, specializing in advanced infectious disease diagnostic services and technologies. The company focuses on developing cutting-edge genomic sequencing, bioinformatics analysis, and machine learning capabilities for rapid bacterial identification and antimicrobial resistance profiling. Their primary offerings to the federal government involve innovative diagnostic solutions that leverage whole genome sequencing and sophisticated computational techniques to quickly determine bacterial species and their antibiotic susceptibility profiles.
In terms of federal contract awards, Day Zero Diagnostics has engaged with the National Institutes of Health (NIH) Clinical Center, specifically receiving a firm fixed-price purchase order contract valued at $13,925 for diagnostic testing services needed by the Department of Laboratory Medicine. The contract, set to be completed by November 24, 2024, does not have a specific set-aside designation. The company has also participated in subcontract work with Trustees of Boston University, developing culture-free, sequencing-based diagnostics that can identify bacterial infections and their antibiotic resistance profiles within hours, even when only a few bacterial cells are present in a sample.
Regarding federal grant awards, Day Zero Diagnostics has received multiple project grants from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program. These grants have supported the development of innovative diagnostic technologies, including EPIXACT-FMT, a metagenomic pharmacovigilance assay for microbiota therapeutics safety, and a whole genome sequencing platform for rapid identification and antimicrobial profiling of uropathogens. The grants, ranging from approximately $300,000 to support specific research aims, focus on developing advanced diagnostic workflows that can provide strain-level resolution, rapid pathogen identification, and comprehensive analysis of complex microbiological samples. By collaborating with institutions like Boston University through sub-grant awards, Day Zero Diagnostics continues to advance its technological capabilities in infectious disease diagnostics.
SBA capabilities narrative
DZD is a CLIA lab providing high complexity infectious disease testing services using next generation sequencing and proprietary computational approaches. We focus in particular on bacterial pathogen detection and genomic analysis for organism ID, antibiotic resistance, and healthcare transmission.
Quick answers
Is Day Zero Diagnostics Inc. registered in SAM.gov?
Day Zero Diagnostics Inc.'s SAM.gov registration expired on February 13, 2026.
How much has Day Zero Diagnostics Inc. received in federal contracts?
Federal contracts obligated $13,925 to Day Zero Diagnostics Inc. in fiscal years 2023 through 2027.
What is Day Zero Diagnostics Inc.'s most recent federal award?
Day Zero Diagnostics Inc.'s most recent federal contract award is Day zero diagnostics testing services needed by the department of laboratory medicine (DLM) for existing project (75N90024P00676), from NIH Clinical Center, on September 25, 2024.
On GovTribe
See Day Zero Diagnostics Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors